Literature DB >> 11280739

XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.

E Asselin1, G B Mills, B K Tsang.   

Abstract

Chemoresistance is a major hurdle for successful cancer therapy. Although multiple mechanisms have been implicated to be involved in cisplatin resistance, recent evidence has suggested that X-linked inhibitor of apoptosis protein (XIAP) may be a key determinant in chemosensitivity in ovarian cancer. Cell fate is determined by a balance between cell survival and apoptotic signaling. Whereas phosphatidylinositol 3-kinase (PI 3-K) and XIAP are believed to be important cell survival factors in human ovarian surface epithelial cancer cells, if and how they interact to confer resistance to chemotherapy is not known. In the present study, we have investigated the role of XIAP in the regulation of the PI 3-K/Akt survival pathway in chemosensitive (A2780-s, OV2008, and OVCAR-3) and resistant (A2780-cp) ovarian cancer cell lines and the nature of this interaction in cell death/survival signaling. Cisplatin decreased XIAP protein levels and induced Akt cleavage and apoptosis in chemosensitive, but not in resistant, ovarian cancer cells. Cisplatin also induced cleavage of caspase-9 and caspase-3, a process blocked by XIAP overexpression. Pretreatment of ovarian cancer cells and their whole cell lysate with tetrapeptide inhibitors of caspases in vitro significantly decreased Akt cleavage induced by cisplatin and exogenous active caspase-3. Adenoviral sense XIAP cDNA expression increased XIAP protein levels and increased Akt phosphorylation, indicative of activation of Akt and, likely, of PI 3-K. This was associated with a decrease in cisplatin-induced apoptosis. In a cell line (OVCAR-3) where basal phosphorylated Akt levels were high, XIAP overexpression failed to increase further the level of this phosphoprotein. XIAP down-regulation induced Akt cleavage and apoptosis, and treatment of whole cell lysate with human recombinant active caspase-3 resulted in a similar pattern of Akt cleavage. In the presence of the PI 3-K inhibitor (LY294002), XIAP overexpression failed to block cisplatin-induced apoptosis and to induce Akt phosphorylation, suggesting that the site of action of XIAP is upstream of Akt in this cell survival pathway. Taken together, the results indicate that XIAP prevents apoptosis through a PI 3-K-dependent inhibition of the caspase cascade. These results demonstrate a novel mechanism by which XIAP regulates apoptosis and the possible involvement of the PI 3-K/Akt survival pathway in XIAP-mediated chemoresistance of ovarian cancer cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11280739

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  117 in total

1.  Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy.

Authors:  Yayoi Kinoshita; Tamara Kalir; Jamal Rahaman; Peter Dottino; D Stave Kohtz
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

2.  The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells.

Authors:  Ke Long Jin; Jeong-Yeol Park; Eun Joo Noh; Kwang Lae Hoe; Joo Hak Lee; Jong-Hyeok Kim; Joo-Hyun Nam
Journal:  J Gynecol Oncol       Date:  2010-12-31       Impact factor: 4.401

3.  Proapoptotic protein Smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101.

Authors:  Wenbin Hu; Fang Wang; Jingsheng Tang; Xinyu Liu; Zhu Yuan; Chunlai Nie; Yuquan Wei
Journal:  J Biol Chem       Date:  2011-11-03       Impact factor: 5.157

4.  Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion.

Authors:  Chun Jiang; Xiao-Ping Yi; Hong Shen; Yi-Xiong Li
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

5.  DNA damage detected with gammaH2AX in endometrioid adenocarcinoma cell lines.

Authors:  Maki Ikeda; Akira Kurose; Eriko Takatori; Toru Sugiyama; Frank Traganos; Zbigniew Darzynkiewicz; Takashi Sawai
Journal:  Int J Oncol       Date:  2010-05       Impact factor: 5.650

Review 6.  Killing of cancer cells through the use of eukaryotic expression vectors harbouring genes encoding nucleases and ribonuclease inhibitor.

Authors:  Elena M Glinka
Journal:  Tumour Biol       Date:  2015-04-01

7.  Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines.

Authors:  Karen Bräutigam; Julia Biernath-Wüpping; Dirk O Bauerschlag; Constantin S von Kaisenberg; Walter Jonat; Nicolai Maass; Norbert Arnold; Ivo Meinhold-Heerlein
Journal:  J Cancer Res Clin Oncol       Date:  2010-09-29       Impact factor: 4.553

8.  Association of XIAP and P2X7 receptor expression with lymph node metastasis in papillary thyroid carcinoma.

Authors:  Li-Qun Gu; Feng-Ying Li; Lin Zhao; Yun Liu; Qian Chu; Xun-Xiong Zang; Jian-Min Liu; Guang Ning; Yong-Ju Zhao
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

9.  Overexpression of DDB2 enhances the sensitivity of human ovarian cancer cells to cisplatin by augmenting cellular apoptosis.

Authors:  Bassant M Barakat; Qi-En Wang; Chunhua Han; Keisha Milum; De-Tao Yin; Qun Zhao; Gulzar Wani; El-Shaimaa A Arafa; Mohamed A El-Mahdy; Altaf A Wani
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

10.  Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling.

Authors:  Liyun Cao; Daniela N Petrusca; Minati Satpathy; Harikrishna Nakshatri; Irina Petrache; Daniela Matei
Journal:  Carcinogenesis       Date:  2008-07-29       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.